Literature DB >> 2440031

A human beta-actin expression vector system directs high-level accumulation of antisense transcripts.

P Gunning, J Leavitt, G Muscat, S Y Ng, L Kedes.   

Abstract

We have constructed a mammalian expression vector consisting of 3 kilobases of the human beta-actin gene 5' flanking sequence plus 5' untranslated region and intervening sequence 1 linked at the 3' splice site to a short DNA polylinker sequence containing unique Sal I, HindIII, and BamHI restriction endonuclease sites followed by a simian virus 40 (SV40) polyadenylylation signal. Two derivatives, containing the selection markers obtained from pSV2gpt or pSV2neo, were also generated. We find that the promoter activity of this vector is a great or greater than that of the SV40 early promoter in a variety of human and rodent cells. The vector was used to generate gamma-actin and beta-tubulin antisense transcripts in human fibroblast cell lines. The antisense transcripts accumulate to levels comparable with that of the highly abundant gamma-actin and beta-tubulin mRNAs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440031      PMCID: PMC305199          DOI: 10.1073/pnas.84.14.4831

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Histone gene expression during sea urchin embryogenesis: isolation and characterization of early and late messenger RNAs of Strongylocentrotus purpuratus by gene-specific hybridization and template activity.

Authors:  G Childs; R Maxson; L H Kedes
Journal:  Dev Biol       Date:  1979-11       Impact factor: 3.582

2.  Transcriptional and cell cycle-mediated regulation of myosin heavy chain gene expression during muscle cell differentiation.

Authors:  R M Medford; H T Nguyen; B Nadal-Ginard
Journal:  J Biol Chem       Date:  1983-09-25       Impact factor: 5.157

3.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

4.  New M13 vectors for cloning.

Authors:  J Messing
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Skeletal muscle actin mRNA. Characterization of the 3' untranslated region.

Authors:  M Shani; U Nudel; D Zevin-Sonkin; R Zakut; D Givol; D Katcoff; Y Carmon; J Reiter; A M Frischauf; D Yaffe
Journal:  Nucleic Acids Res       Date:  1981-02-11       Impact factor: 16.971

6.  A fetal skeletal muscle actin mRNA in the mouse and its identity with cardiac actin mRNA.

Authors:  A J Minty; S Alonso; M Caravatti; M E Buckingham
Journal:  Cell       Date:  1982-08       Impact factor: 41.582

7.  Expression of a variant form of actin and additional polypeptide changes following chemical-induced in vitro neoplastic transformation of human fibroblasts.

Authors:  J Leavitt; T Kakunaga
Journal:  J Biol Chem       Date:  1980-02-25       Impact factor: 5.157

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase.

Authors:  R C Mulligan; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

10.  A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.

Authors:  H Okayama; P Berg
Journal:  Mol Cell Biol       Date:  1983-02       Impact factor: 4.272

View more
  232 in total

Review 1.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

2.  Suppression of E1A-mediated transformation by the p50E4F transcription factor.

Authors:  E R Fernandes; R J Rooney
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

3.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions.

Authors:  K V Vijayan; P J Goldschmidt-Clermont; C Roos; P F Bray
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

5.  A genetic screen identifies novel non-compatible loxP sites.

Authors:  Stephen J Langer; A Paiman Ghafoori; Marshall Byrd; Leslie Leinwand
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

6.  Expression of the human MUC1 mucin cDNA in a hamster pancreatic tumor cell line HP-1.

Authors:  S K Batra; R S Metzgar; A J Worlock; M A Hollingsworth
Journal:  Int J Pancreatol       Date:  1992-12

7.  Terminal differentiation in keratinocytes involves positive as well as negative regulation by retinoic acid receptors and retinoid X receptors at retinoid response elements.

Authors:  B J Aneskievich; E Fuchs
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

8.  Raf-1 protein kinase is an integral component of the oncogenic signal cascade shared by epidermal growth factor and platelet-derived growth factor.

Authors:  S Kizaka-Kondoh; K Sato; K Tamura; H Nojima; H Okayama
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

9.  Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.

Authors:  C J Chen; A C Banerjea; G G Harmison; K Haglund; M Schubert
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

10.  Expression of the CD4 gene requires a Myb transcription factor.

Authors:  G Siu; A L Wurster; J S Lipsick; S M Hedrick
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.